StudyFinder
A Phase I/IIa, First-in-Human, Multicenter, Monotherapy and Combination-Therapy with Nivolumab, Dose-Finding and Dose-Expansion Study of (212Pb)VMT01 Melanocortin-1-Receptor-Targeted, Image-Guided, Alpha-Particle Therapy in Subjects with Previously Treated Unresectable or Metastatic Melanoma (VMT01-T101)
Status: Recruiting
This study is testing a radioactive treatment for adults with advanced melanoma that has spread, cannot be removed by surgery, or has gotten worse after prior treatment. We want to learn how safe the treatment is and how well it may work. By taking part, participants may help us learn whether this could become a useful treatment option for people with advanced melanoma.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• ages 18 or older
• diagnosed with advanced melanoma that cannot be removed by surgery, has spread, or has returned
• previously received at least one approved treatment for advanced melanoma and had the cancer worsen
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:
• have another active cancer
• are pregnant or breastfeeding
• have previously received systemic treatment with radioactive medicines
• see link to clinicaltrials.gov for complete exclusion criteria
Interventions:
Drug: Nivolumab, Drug: [203Pb]VMT01, Drug: [212Pb]VMT01
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Cancer, Melanoma, Nivolumab
Study Contact: Benjamin Manning - mann0233@umn.edu
Principal Investigator: Benjamin Manning
Phase: PHASE1
IRB Number: STUDY00025911
See this study on ClinicalTrials.gov